The involvements of the chromatin remodeling-related pathway, BET inhibitor, and BRD4 expression in PRDM1-high stomach cancer galvanized us to test whether these associations could be validated in wet-lab assembly using SNU-1: the human stomach cancer cell line with high PRDM1 expression and level 1 biosafety. This evidence concerns the gene PRDM1 and gastric cancer.